Insmed Incorporated
0JAV.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.92B
Close$
Share Statistics
| Market cap | $21.92 Billion |
|---|---|
| Enterprise Value | $21.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.42 |
| Beta | 0.79 |
| Outstanding Shares | 217,352,000 |
Return
| Return on Equity | -115.55% |
|---|---|
| Return on Assets | -41.63% |
| Return on Invested Capital | -51.51% |
Valuation & Multiples
| P/E Ratio | -24.48 |
|---|---|
| PEG | 25.53 |
| Price to Sales | 19.39 |
| Price to Book Ratio | 32.31 |
| Enterprise Value to Revenue | 18.82 |
| Enterprise Value to EBIT | -24.98 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
$395.50 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$497.11 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Insmed Inc
1,664 employees
CEO: William Lewis Insmed Incorporated is a biopharmaceutical company primarily focused on discovering, developing, and marketing therapeutic solutions for individuals afflicted with severe and rare medical conditions. The company's marketed product, ARIKA...